Ferring calls for sanctions on Jones Day
11-03-2021
Fed Circuit remands Allergan inventorship dispute
11-11-2020
Will Big Pharma get the bug for microbiome therapies?
06-05-2020
Chinese institute tries to patent Gilead coronavirus drug
06-02-2020
Oleschwander / Shutterstock.com
Swiss-based Ferring Pharmaceuticals has prevailed in a patent dispute with rivals Serenity Pharmaceuticals and Reprise Biopharmaceuticals over a nighttime urination, or nocturia, treatment.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Ferring, Serenity, Reprise, Nocdurna, desmopressin, FDA, nocturia, patents, invalidation, inventor
